Ocular Therapeutix Q2 net product rev $12.1M (+9% YoY); net loss $18.8M; FY guidance reaffirmed

OCULAR THERAPEUTIX, INC

2022-Q2 EPS reported -$0.47 revenue$25,453,000

DEXTENZA net product revenue $12.1M in Q2 2022, up 9% YoY from $11.1M; total net revenue $12.3M.
Net loss $18.8M ($0.24 basic / $0.25 diluted EPS) vs $8.5M loss in Q2 2021.
Reiterates FY2022 DEXTENZA net product revenue guidance of $55-60M (26%-38% growth).
Cash and equivalents $134.5M at June 30, 2022; expects to fund operations through 2023.
Interim OTX-TKI (wet AMD) Phase 1 data to be presented at AAO in September 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.